摘要
异基因造血干细胞移植(allo-HSCT)是治愈血液系统疾病的一种有效方法。血小板减少是allo-HSCT后常见且严重的并发症,与预后不良相关。成分血输注、促进血小板生成及释放药物、糖皮质激素等可用于allo-HSCT后血小板减少的治疗,但疗效有限。近年来,随着对allo-HSCT后血小板减少发病机制的研究,间充质干细胞(MSCs)及血小板生成素受体激动剂(TPO-RA)已作为其治疗选择,且证明安全有效。本文就MSCs联合TPO-RA在allo-HSCT后血小板恢复中的作用机制及安全性和有效性进行综述。
Allogeneic hematopoietic stem cell transplantation(allo-HSCT)is an effective method to cure hematological diseases.Thrombocytopenia associated with a poor prognosis is a common but severe complication after allo-HSCT.Blood component transfusion,drugs that promote platelet production and release,and glucocorticoids can treat thrombocytopenia after allo-HSCT,but the efficacy is limited.In recent years,with the study of the pathogenesis of thrombocytopenia after allo-HSCT,mesenchymal stem cells(MSCs)and thrombopoietin receptor agonists(TPO-RA)have been used as their treatment options and have proved to be safe and effective.This article reviews the mechanism of action,safety and efficacy of MSCs combined with TPO-RA in platelet recovery after allo-HSCT.
作者
刘文慧
吴涛
张曦
Wenhui Liu;Tao Wu;Xi Zhang(Department of Hematology,the 940th Hospital of Joint Logistics Support Force of the Chinese People's Liberation Army,Lanzhou 730050,China;Department of Hematology,Second Affiliated Hospital of Army Medical University of Chinese People's Liberation Army,Chongqing 400037,China)
出处
《中华细胞与干细胞杂志(电子版)》
2023年第4期242-246,共5页
Chinese Journal of Cell and Stem Cell(Electronic Edition)
基金
甘肃省创新基地和人才计划(甘肃省白血病临床医学研究中心)资助(21JR7RA015)。